Cargando…

Gadoxetic acid–enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C

BACKGROUND: Paritaprevir inhibits organic anion–transporting polypeptide (OATP)1B1 and OATP1B3, which transport bilirubin. Hyperbilirubinemia is an adverse event reported during hepatitis C treatment. Gadoxetic acid is also transported by OATP1B1/1B3. We evaluated whether the enhancement effect in g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okubo, Hironao, Ando, Hitoshi, Sorin, Yushi, Nakadera, Eisuke, Fukada, Hiroo, Morishige, Junichi, Miyazaki, Akihisa, Ikejima, Kenichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927452/ https://www.ncbi.nlm.nih.gov/pubmed/29709031 http://dx.doi.org/10.1371/journal.pone.0196747

Ejemplares similares

Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment
por: Okubo, Hironao, et al.
Publicado: (2022)

Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis
por: Okubo, Hironao, et al.
Publicado: (2021)

Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma
por: Okubo, Hironao, et al.
Publicado: (2022)

The Impact of Partial Splenic Embolization on Portal Hypertensive Gastropathy in Cirrhotic Patients with Portal Hypertension
por: Saeki, Michio, et al.
Publicado: (2023)

Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma
por: Okubo, Hironao, et al.
Publicado: (2020)

L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy
por: Jing, Zheng, et al.
Publicado: (2023)

Gadoxetic acid magnetic-enhanced resonance imaging in the diagnosis of cholangiocarcinoma
por: Inchingolo, Riccardo, et al.
Publicado: (2020)

Endobronchial Watanabe Spigot Placement for Hepatic Abscess and Bronchobiliary Fistula Following Radiofrequency Ablation for Hepatocellular Carcinoma
por: Nishioki, Toshihiko, et al.
Publicado: (2022)

Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients
por: Loo, Nicole, et al.
Publicado: (2019)

Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers
por: Kim, Yeun-Yoon, et al.
Publicado: (2019)

Shrunken Hepatic Hemangioma Following Delineated Peritumoral Hyperintensity on Gadoxetic Acid Disodium-enhanced MR Imaging
por: Haradome, Hiroki, et al.
Publicado: (2017)

The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1
por: Miyasaka, Akio, et al.
Publicado: (2018)

Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED
por: Bu, G, et al.
Publicado: (2023)

Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
por: Ren, Rui, et al.
Publicado: (2023)

Primary hepatic neuroendocrine tumor: gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging
por: Baek, Soo-heui, et al.
Publicado: (2013)

Diagnosis of Cholecysto-Colonic Fistula Using Gadoxetic Acid – Magnetic Resonance Cholangiography
por: Mourri, A. B., et al.
Publicado: (2015)

Circulating microRNA-636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir
por: Morishita, Asahiro, et al.
Publicado: (2018)

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
por: Badri, Prajakta S., et al.
Publicado: (2015)

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
por: Bernstein, David E., et al.
Publicado: (2018)

Neonatal hyperbilirubinemia
por: Ben, Matteo Dal, et al.
Publicado: (2014)

Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus
por: Danilau, Dzmitry, et al.
Publicado: (2017)

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia
por: Forns, Xavier, et al.
Publicado: (2015)

The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp
por: Gurung, Arun Bahadur, et al.
Publicado: (2021)

The utility of gadoxetic acid-enhanced magnetic resonance imaging in the surveillance for postoperative recurrence of hepatocellular carcinoma
por: Kim, Jung Hee, et al.
Publicado: (2016)

Hyperbilirubinemia and Pelvicaliceal Dilatation
por: Wiwanitkit, Viroj
Publicado: (2012)

Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection
por: Smith, Michael A, et al.
Publicado: (2015)

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir
por: Schnell, Gretja, et al.
Publicado: (2017)

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

Differentiating Focal Eosinophilic Infiltration from Metastasis in the Liver with Gadoxetic Acid-Enhanced Magnetic Resonance Imaging
por: Lee, Mi Hee, et al.
Publicado: (2011)

Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging for the Detection of Hepatocellular Carcinoma: A Meta-Analysis
por: Liu, Xijiao, et al.
Publicado: (2013)

Magnetic resonance imaging of liver tumors using gadoxetic acid (Gd-EOB-DTPA) - pilot study
por: Borusewicz, Pola, et al.
Publicado: (2019)

Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma
por: Chou, Yi-Chen, et al.
Publicado: (2019)

Optimization of hepatobiliary phase imaging in gadoxetic acid-enhanced magnetic resonance imaging: a narrative review
por: Wang, Chao, et al.
Publicado: (2023)

Unexpected uptake of gadoxetic acid in a hepatic metastasis from T-cell lymphoma
por: Song, Won S., et al.
Publicado: (2012)

Histogram Analysis of Gadoxetic Acid-Enhanced MRI for Quantitative Hepatic Fibrosis Measurement
por: Kim, Honsoul, et al.
Publicado: (2014)

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir
por: Krishnan, Preethi, et al.
Publicado: (2016)

On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series
por: Bean, Madelyne, et al.
Publicado: (2016)

Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/Ritonavir
por: Schnell, Gretja, et al.
Publicado: (2015)

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients
por: Chayama, Kazuaki, et al.
Publicado: (2015)

Fibrosis Progression and Incidence of Cirrhosis and Hepatic Decompensation in Persons Treated with Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir: Results from ERCHIVES
por: Simon, Tracey, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5gr6m4kkf0lqd5jfrp3njjvrin